Implementing Changes in Pharmacovigilance Regulations. Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016

Size: px
Start display at page:

Download "Implementing Changes in Pharmacovigilance Regulations. Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016"

Transcription

1 s Presented by Dr Ennis H Lee, Senior Partner, TranScrip 14 June 2016

2 Monitor for changes in regulations Regulatory Authority websites Pharmaceutical industry bodies Pharmaceutical press Use global subsidiaries An Indegene and TranScrip alliance Private & Confidential 2

3 Get involved in shaping new regulation Review legislation and guidance documents Comment directly to Regulatory Authorities Comment via industry bodies Attend Regulatory Authority briefing meetings An Indegene and TranScrip alliance Private & Confidential 3

4 Communicate change Up - Senior Management Down Staff / Contractors Sideways Global subsidiaries Licence partners Vendors An Indegene and TranScrip alliance Private & Confidential 4

5 Updating of EU PV Legislation Extensive changes to EU PV regulation started with legislation implementation in 2012 Major changes to the requirements for a company PV System were needed Change is still ongoing and will be for some time IT systems to support PV still not operational Resource is a major challenge for all An Indegene and TranScrip alliance Private & Confidential 5

6 Challenges of the EU legislation change Change in the definition of ADR Requirements to collect AEs medication errors, overdose, abuse, etc. New signal management needs New format safety documents DSUR, EU-RMP, etc. Pharmacovigilance System Master File Requirements for global safety data, documenting global PV vendors, Partner agreements, etc. Audit requirements and documentation An Indegene and TranScrip alliance Private & Confidential 6

7 Global PV System One global assessment of drug safety Global standards, labelling, etc Data from global company sources Global company databases Actions in one country affect all other countries Document pharmacovigilance practice and standards An Indegene and TranScrip alliance Private & Confidential 7

8 Task Forces Get buy-in from and set up feedback mechanism to senior management Appoint an influential chair and a lead for each function Charter of goals and activities Manage an action list and costings Site for all documentation Feedback from all functions on how changes will influence their practice, if at all Expect challenges! An Indegene and TranScrip alliance Private & Confidential 8

9 Assess change needed Assess regulatory and guidance documents one function leading: Assess changes needed Consider impact on other countries Will IT systems help? Knock-on effects to Partners, Vendors, etc Allocate actions for each function An Indegene and TranScrip alliance Private & Confidential 9

10 Make an implementation plan What needs to change What When By whom Transition plan Communication plan Costings for change Feedback for senior management An Indegene and TranScrip alliance Private & Confidential 10

11 Controlled documents Review all current controlled document for changes Appoint a lead for all updates and new documents Set timelines Mechanism to roll-out to relevant staff groups Assess compliance with training real-time Set criteria to measure effectiveness and measure An Indegene and TranScrip alliance Private & Confidential 11

12 Training and roll-out Communication plan Explain need and how change will be managed Assess training needs globally by function Set challenging but realistic goals Management oversight of compliance Set Goals and Objectives for staff globally Ongoing CPD requirements An Indegene and TranScrip alliance Private & Confidential 12

13 Implementation Set dates for changes Regularly assess progress against the plan Document change and inform Regulatory Authorities of changes as required Regularly feedback Senior management (reports) Staff globally (newsletters) Minimise confusion! An Indegene and TranScrip alliance Private & Confidential 13

14 Audit, review and update Internal audit plan to review new processes and practices as part of implementation Audit by both process and function Regularly feedback to senior management Manage a CAPA process to ensure compliance with required changes Update processes and repeat the cycle of change management and audit An Indegene and TranScrip alliance Private & Confidential 14

15 The challenges of Pharmacovigilance! An Indegene and TranScrip alliance Private & Confidential 15

Guidance notes for patient safety and pharmacovigilance in patient support programmes

Guidance notes for patient safety and pharmacovigilance in patient support programmes Guidance notes for patient safety and pharmacovigilance in patient support programmes Authors: The ABPI Pharmacovigilance Expert Network Version: 2.14 Date: March 2018 Acknowledgements: We thank the many

More information

Safeguarding public health. The New PV Legislation. Perspective from a Member State

Safeguarding public health. The New PV Legislation. Perspective from a Member State Safeguarding public health The New PV Legislation Perspective from a Member State Mick Foy Reinforcing patient safety in Europe, Zagreb June 2011 Content Background The new EU PV Package ADR Definition

More information

Corporate Induction: Part 2

Corporate Induction: Part 2 Corporate Induction: Part 2 Identification of preventable Adverse Drug Reactions from a regulatory perspective March 1 st 2013, EMA Workshop on Medication Errors Presented by Almath Spooner, Pharmacovigilance

More information

The New EU PV Legislation: View from the European Commission

The New EU PV Legislation: View from the European Commission The New EU PV Legislation: View from the European Commission International seminar 26 May 2011 Lenita LINDSTRÖM Senior Policy Officer Pharmaceuticals Unit/DG SANCO Rationale for the revision Calls for

More information

TRAINING CALENDAR 2018

TRAINING CALENDAR 2018 TRAINING CALENDAR 2018 Quality Efficiency Innovation CLINICAL RESEARCH AND COMPLIANCE 9 July Data Integrity Assessment WORKSHOP An effective approach to identify data integrity gaps on some pratical examples

More information

Pharmacovigilance documents in the life cycle of a medicinal product: DSUR, RMP, PSUR/PBRER, and Addendum to the Clinical Overview

Pharmacovigilance documents in the life cycle of a medicinal product: DSUR, RMP, PSUR/PBRER, and Addendum to the Clinical Overview From patients to health authorities: data collection, signal management, document preparation, authority assessment 210 Early Bird discount for enrolment by 12 th June 2018 Hotel Melià Via Masaccio 19

More information

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS

BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS A2 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI): FIFTH REPORT ON PROGRESS March 2012 A3 BETTER REGULATION OF MEDICINES INITIATIVE (BROMI) FIFTH REPORT ON PROGRESS Chief Executive s foreword In January

More information

Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective

Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions

More information

Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016

Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016 Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016 Helen Lee European Commission, Health and Food Safety Directorate General Outline of the presentation Characterisitics of

More information

Safeguarding public health. The New PV Legislation its Impact on PV & MI

Safeguarding public health. The New PV Legislation its Impact on PV & MI Safeguarding public health The New PV Legislation its Impact on PV & MI Sarah Vaughan - MHRA PIPA 2013 Manager s Meeting 13 th February 2013 Content Scope of change Key areas - ADR reporting - DDPS to

More information

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE

FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : FDA/SMC/SMD/GL-QPP/2013/03 Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version

More information

Good Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA

Good Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA Good Pharmacovigilance Practice Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA Content ADR Reporting Definition & Increased scope Transition arrangements

More information

New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)

New Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) New Streams of Risk Management Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are

More information

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist

Pharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist Curriculum vitae PERSONAL INFORMATION Gyorgyi Fodor WORK EXPERIENCE September 2011 Present Pharmacovigilance assessor National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Benefit/risk assessment,

More information

Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013

Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013 Implementation of the new pharmacovigilance legislation: Overall update and activities in 2013 Workshop for micro, small and medium-sized enterprises (SMEs) European Medicines Agency (EMA), London 26 April

More information

WHO Pharmacovigilance Indicators. Dr. Nitin Gaikwad Co-coordinator, ADR Monitoring Center, PvPI Additional Professor, Pharmacology AIIMS Raipur

WHO Pharmacovigilance Indicators. Dr. Nitin Gaikwad Co-coordinator, ADR Monitoring Center, PvPI Additional Professor, Pharmacology AIIMS Raipur WHO Pharmacovigilance Indicators Dr. Nitin Gaikwad Co-coordinator, ADR Monitoring Center, PvPI Additional Professor, Pharmacology AIIMS Raipur Scope of presentation Sensitization of Coordinators, Co-coordinators,

More information

Continuous Professional Development of Health Professionals European Context

Continuous Professional Development of Health Professionals European Context Continuous Professional Development of Health Professionals European Context Balázs Lengyel European Commission Health and Food Safety Directorate-General 20 June 2017 Citizens opinion: "Well trained medical

More information

GCP INSPECTORATE GCP INSPECTIONS METRICS REPORT

GCP INSPECTORATE GCP INSPECTIONS METRICS REPORT GCP INSPECTORATE GCP INSPECTIONS METRICS REPORT METRICS PERIOD: 1 st April 1 to 31 st March 11 DATE OF ISSUE: 1 th March 1 MHRA Central Region Medicines Inspectorate Falcon Way, Shire Park Welwyn Garden

More information

Pharmacovigilance Training

Pharmacovigilance Training Pharmacovigilance Training Pharmacovigilance Roche systematically monitors the benefit/risk of its products. As a part of this monitoring process, in case you/your company become aware of Adverse Events

More information

WHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety

WHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety WHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety Birth of WHO Drug Monitoring Programme Thalidomide Phocomelia 2 16th World Health Assembly 1963 Assembly Resolution

More information

Teleconference Course Materials You may duplicate this for each person attending the conference.

Teleconference Course Materials You may duplicate this for each person attending the conference. TC001603A Teleconference Course Materials You may duplicate this for each person attending the conference. Show Me Your Safety Data... FDA & EU Pharmacovigilance Inspections by Steve Jolley SJ Pharma Consulting

More information

1. PURPOSE 2. SCOPE 3. RESPONSIBILITIES

1. PURPOSE 2. SCOPE 3. RESPONSIBILITIES 1. PURPOSE The purpose of this standard operating procedure (SOP) is to inform all Alexion personnel, and applicable service providers who become aware of a Pharmacovigilance (PV) Event of their responsibility

More information

Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes

Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes 2 nd Adverse Event Reporting and Safety Strategies Summit December 8-9, 2015

More information

Measures of impact of pharmacovigilance processes (3.3)

Measures of impact of pharmacovigilance processes (3.3) Measures of impact of pharmacovigilance processes (3.3) Session 4 - Reports from breakout sessions: gaps and observations Workshop: Measuring the Impact of Pharmacovigilance Activities London, 5-6 December

More information

ZAMBIA MEDICINES REGULATORY AUTHORITY EMPLOYMENT OPPORTUNITY

ZAMBIA MEDICINES REGULATORY AUTHORITY EMPLOYMENT OPPORTUNITY ZAMBIA MEDICINES REGULATORY AUTHORITY EMPLOYMENT OPPORTUNITY The Zambia Medicines Regulatory Authority (ZAMRA) was set up by the Medicines and Allied Substances Act (No. 3) of 2013 as a statutory body

More information

MedDRA Coding and Medication Error Topics. Patrick Revelle (MSSO)

MedDRA Coding and Medication Error Topics. Patrick Revelle (MSSO) MedDRA Coding and Medication Error Topics Patrick Revelle (MSSO) Topics for Presentation MSSO's MedDRA maintenance role MedDRA's history with medication errors Developmental efforts FAERS and ICSRs MedDRA

More information

Overview of Draft Pharmacovigilance Protocol

Overview of Draft Pharmacovigilance Protocol Overview of Draft Pharmacovigilance Protocol Identifying ADRs in Africa Special Challenges Malaria - pan-systemic clinical features Life-threatening condition Real-world trial AS/SP and co-artem safety

More information

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM 003 SOP category: Trial Management Version number: 03 Version date:

More information

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA

The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA The Pharmaceutical Risk Assessment Committee (PRAC) of the EMA Albert van der Zeijden (PRAC member) Expert representing patients perspective Eurordis Summerschool Friday June 5, 2015 Content The history

More information

District of Columbia Prescription Drug Monitoring Program

District of Columbia Prescription Drug Monitoring Program District of Columbia Prescription Drug Monitoring Program What Our Users Need to Know Health Regulation and Licensing Administration Pharmaceutical Control Division February 28, 2017 1 Mission Statement

More information

Sponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law

Sponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK

More information

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM-003 SOP category: Trial Management Version number: 04 Version date:

More information

Changing Requirements for Devices//Device Constituent Parts in Combination Products

Changing Requirements for Devices//Device Constituent Parts in Combination Products Changing Requirements for Devices//Device Constituent Parts in Combination Products Dan Wozinski, RPH, MBA Sanofi Disclaimer The content and viewpoints of this presentation are mine alone and not those

More information

Marie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager

Marie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:

More information

Quality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D

Quality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially

More information

INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT. Susanna Palkonen, EPF Board Member

INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT. Susanna Palkonen, EPF Board Member INVOLVING PATIENTS IN PHARMACOVIGILANCE EPF TOOLKIT Susanna Palkonen, EPF Board Member EPF About us Independent, non-governmental umbrella organisation set up in 2003 VISION: High-quality, patientcentred,

More information

Pharmacovigilance in Kenya

Pharmacovigilance in Kenya Pharmacovigilance in Kenya Dr. Dorine Kagai (NASCOP) Mr. George Muthuri (PPB) Ministry of Medical Services 23 nd November, 2009 ARV PV TRAINING TZ ART program. Over 300,000 patients on ARVs: Over 60% female

More information

Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission

Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission Electronic submission of information on medicinal products in accordance to Article 57(2) requirements: Maintenance submission SME workshop: Focus on quality for medicines containing chemical entities

More information

NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) COMMENT

NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) COMMENT 1 NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) SECTION 1. SHORT TITLE. This Act shall be known and may be cited as the

More information

Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine

Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose

More information

What does governance look like in homecare?

What does governance look like in homecare? What does governance look like in homecare? Dr David Cousins PhD FRPharmS Head of Pa)ent Safety, Healthcare at Home Ltd This Satellite is sponsored by Healthcare at Home Ltd Definitions Clinical governance

More information

Issue 7/ Jul - Sept 2012

Issue 7/ Jul - Sept 2012 The Hong Kong Association of the Pharmaceutical Industry Issue 7/9 2012 Jul - Sept 2012 In This Issue September CEO Luncheon Meeting with Dr. Ko Wing-man Joint Event with the Drug Office Visit to Macau

More information

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead: Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of

More information

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014

Adopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014 21 March 2014 EMA/INS/PhV/192231/2014 Union procedure on the management of pharmacovigilance inspection findings which may impact the robustness of the benefit-risk profile of the concerned medicinal Adopted

More information

Safety Reporting in Clinical Research Policy Final Version 4.0

Safety Reporting in Clinical Research Policy Final Version 4.0 Safety Reporting in Clinical Research Policy Final Version 4.0 Category: Summary: Equality Assessment undertaken: Impact Policy The Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent

More information

Do you suffer from diabetes? Do you want to shape the future of diabetes care?

Do you suffer from diabetes? Do you want to shape the future of diabetes care? Do you suffer from diabetes? Do you want to shape the future of diabetes care? MSD has fully funded this project which is a collaboration between MSD, Heart of England Foundation Trust, Lloyds Pharmacy

More information

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted

More information

Pharmacovigilance in Middle East Conference

Pharmacovigilance in Middle East Conference Pharmacovigilance in Middle East Conference Target Audience: 20-21 January, 2012 Yas Rotana Hotel Abu Dhabi UAE HAAD Accredited for 7.25 CME Hours Regulatory Authorities; (Safety Programs, Regulatory affairs)

More information

The National Patient Experience Survey Programme. Statement of information practices

The National Patient Experience Survey Programme. Statement of information practices The National Patient Experience Survey Programme Reference No: NPES-SoIP-02.17 Revision No: 00 Author: Approved by: National Patient Experience Survey team Rachel Flynn, Director of Health Information

More information

New European Union Clinical Trial Regulations

New European Union Clinical Trial Regulations New European Union Clinical Trial Regulations Incorporate Monitoring and Safety Reporting Techniques into U.S. and EU Clinical Trial SOPs Anita K. Murthy Deputy Director, Global Regulatory Affairs Bayer

More information

Pharmacovigilance Office of Product Review

Pharmacovigilance Office of Product Review Pharmacovigilance Office of Product Review Dr Jane Cook Office Head Office of Product Review, Monitoring & Compliance Group, TGA 7/10/2011 Overview of talk Overview Post TGA 21 and OPR New Guidelines Key

More information

2012 Medicare Compliance Plan

2012 Medicare Compliance Plan 2012 Medicare Compliance Plan Document maintained by: Gay Ann Williams Medicare Compliance Officer 1 Compliance Plan Governance The Medicare Compliance Plan is updated annually and is approved by the Boards

More information

Guidance for MRC units on HTA licence applications for storage of human samples for research purposes

Guidance for MRC units on HTA licence applications for storage of human samples for research purposes Guidance for MRC units on HTA licence applications for storage of human samples for research purposes Summary In England, Wales and Northern Ireland the Human Tissue Authority (HTA) is licensing premises

More information

SCOPE Work Package 4 ADR Collection. Medication Errors

SCOPE Work Package 4 ADR Collection. Medication Errors Medication Errors Contents Acknowledgments 3 1. Introduction 4 1.3 Definitions and abbreviations 5 2. Medication errors 7 2.1 Coding of medication errors 7 2.2 Exemption from liability for HCPs when reporting

More information

Compliance Program Updated August 2017

Compliance Program Updated August 2017 Compliance Program Updated August 2017 Table of Contents Section I. Purpose of the Compliance Program... 3 Section II. Elements of an Effective Compliance Program... 4 A. Written Policies and Procedures...

More information

Clinical Research Professionals

Clinical Research Professionals Training & Resources for Clinical Research Professionals Course & Publications Catalog January July 2016 In-Person and Web-Based Training Courses, Customized Training, elearning and Publications for Clinical

More information

Cleaning Manual. Fitzroy Falls aged Care Facility. J.N. Bailey 2009 Fitzroy Falls Aged Care Facility - Cleaning Manual Version 1.0.

Cleaning Manual. Fitzroy Falls aged Care Facility. J.N. Bailey 2009 Fitzroy Falls Aged Care Facility - Cleaning Manual Version 1.0. Cleaning Manual Fitzroy Falls aged Care Facility J.N. Bailey 2009 Fitzroy Falls Aged Care Facility - Cleaning Manual Version 1.0.0 Page 1 of 5 Cleaning Manual Policy and Responsibilities 03 05 Cleaning

More information

MedDRA User Group. Paris, April 16, 2015 Victoria Newbould, European Medicines Agency. An agency of the European Union

MedDRA User Group. Paris, April 16, 2015 Victoria Newbould, European Medicines Agency. An agency of the European Union MedDRA User Group Paris, April 16, 2015 Victoria Newbould, European Medicines Agency An agency of the European Union HMA meeting 28 November 2013 HMA agreed with the deliverables to be completed over the

More information

SCOPE Work Package 4 ADR Collection. Handling Telephone Calls from the Public

SCOPE Work Package 4 ADR Collection. Handling Telephone Calls from the Public ADR Collection Handling Telephone Calls from the Public Contents Acknowledgments 3 1. Introduction 4 1.1 Purpose of the document 4 1.2 Background 4 1.3 Regulatory requirements 6 1.4 Definitions and abbreviations

More information

Patient Centricity In Pharmacovigilance:

Patient Centricity In Pharmacovigilance: Patient Centricity In Pharmacovigilance: New Directions, New Horizons Background The importance of Pharmacovigilance (PV) as a science and its role in effective patient care in clinical practice and public

More information

Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action

Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action www.scopejointaction.eu Strengthening Collaborations for Operating Pharmacovigilance in Europe (SCOPE) Joint Action The SCOPE Joint Action has received funding from the European Union Contents 1. Overall

More information

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS

LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH

More information

Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1

Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 Managing medicines in care homes Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Performance, Innovation, and Improvement Grant Application

Performance, Innovation, and Improvement Grant Application 2017-2018 Performance, Innovation, and Improvement Grant Application OVERVIEW OF THE GRANT AND APPLICATION The Ohio Council of Community Schools (OCCS) is pleased to announce grant opportunities for governing

More information

High level guidance to support a shared view of quality in general practice

High level guidance to support a shared view of quality in general practice Regulation of General Practice Programme Board High level guidance to support a shared view of quality in general practice March 2018 Publications Gateway Reference: 07811 This document was produced with

More information

Provided below is the background, discussion, and recommendations from the panelists.

Provided below is the background, discussion, and recommendations from the panelists. Pharmacovigilance is neither a luxury nor a distraction; it is a necessity Conclusions of a High Level Panel on Access and Patient Safety at the Africa Pharmacovigilance Meeting 2012 held at the Intercontinental

More information

REQUEST FOR PROPOSAL (RFP)

REQUEST FOR PROPOSAL (RFP) REQUEST FOR PROPOSAL (RFP) Stand Up Placer (SUP) is sending you the enclosed invite for your consideration in our RFP process for an Accountant to demonstrate their qualifications for a one-year engagement

More information

General information. Name: Colin Sainsbury

General information. Name: Colin Sainsbury General information Name of Organisation ByrneWallace Contact information Head of Organisation Main contact Name: Catherine Guy (Managing Partner) Address: 88 Harcourt Street, Dublin 2 Telephone: 353 1

More information

Homecare Medicines Charter

Homecare Medicines Charter Purpose of this charter Homecare Medicines Charter The purpose of this charter is to provide you with information on homecare medicines services. It will include the steps you will go through and what

More information

WHO role in the introduction of new TB drugs and regimens: (2) Supporting introduction in countries

WHO role in the introduction of new TB drugs and regimens: (2) Supporting introduction in countries WHO role in the introduction of new TB drugs and regimens: (2) Supporting introduction in countries GDI/GLI Meeting Session 3 Geneva 27 th April 2015 Christian Lienhardt Global TB Programme World Health

More information

The Strategic Content Alliance. Sustaining Digital Resources

The Strategic Content Alliance. Sustaining Digital Resources The Strategic Content Alliance Sustaining Digital Resources The Strategic Content Alliance Sustaining Digital Resources Sarah Fahmy Manager, Strategic Content Alliance www.jisc.ac.uk/contentalliance 08

More information

IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES

IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES DOCUMENT NO.: CR012 v2.0 AUTHOR: Raymond French ISSUE DATE: 18 September 2017 EFFECTIVE DATE: 02 October

More information

Improving the Safety of International Non-proprietary Names of Medicines (INNs) Position Statement 2011

Improving the Safety of International Non-proprietary Names of Medicines (INNs) Position Statement 2011 Improving the Safety of International Non-proprietary Names of Medicines (INNs) Position Statement 2011 The International Patient Safety Network The International Medication Safety Network (IMSN) is an

More information

Standard Operating Procedure

Standard Operating Procedure Standard Operating Procedure SOP number: SOP full title: SOP-JRO-07-004 Recording, managing and reporting Adverse Events for Clinical Trials of Investigational Medicinal Products and trials of Advanced

More information

Current Status: Active PolicyStat ID: Origination: 09/2004 Last Approved: 02/2017 Last Revised: 09/2013 Next Review: 02/2019

Current Status: Active PolicyStat ID: Origination: 09/2004 Last Approved: 02/2017 Last Revised: 09/2013 Next Review: 02/2019 Current Status: Active PolicyStat ID: 3092101 Origination: 09/2004 Last Approved: 02/2017 Last Revised: 09/2013 Next Review: 02/2019 Owner: Policy Area: References: Applicability: Bill Mayher: SVP - Reg

More information

Administrative services which may be delegated to IPAs, Medical Groups, Vendors, or other organizations include:

Administrative services which may be delegated to IPAs, Medical Groups, Vendors, or other organizations include: Delegation Delegation This section contains information specific to medical groups, Independent Practice Associations (IPA), and Vendors contracted with Molina to provide medical care or services to Members,

More information

Required Activities (continued)

Required Activities (continued) DMAS-CMHRS Manual Services based upon incomplete, missing, or outdated (more than a year old or not reflective of the individuals current level of need) intakes/re-assessments and ISPs shall be denied

More information

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager

R. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager Standard Operating Procedures (SOP) for: BH/QMUL Sponsorship of CTIMPs, ATMPs and Clinical Trials of non- CE marked Medicinal Devices Process for Researchers SOP Number: 11a Version Number: V1.0 Effective

More information

POST-LAUNCH DEMANDS: Dr Thomas Lönngren ISPOR Content

POST-LAUNCH DEMANDS: Dr Thomas Lönngren ISPOR Content POST-LAUNCH DEMANDS: HOW CAN A COMPANY BEST ADDRESS THE CHALLENGES AND OPPORTUNITIES PRESENTED BY THE NEW EU PHARMACOVIGILANCE REQUIREMENTS OF THE REGULATORS, THE ASSESSOR S NEED FOR REAL WORLD EVALUATION,

More information

Self-assessment worksheet for the Professional Practice Standards version 4

Self-assessment worksheet for the Professional Practice Standards version 4 Self-assessment worksheet for the Professional Practice Standards version The following self-assessment worksheet and the Professional Practice Standards version are intended to serve as a guide to achieving

More information

Baltimore-Towson EMA Part A Quality Management (QM) Plan I. Introduction

Baltimore-Towson EMA Part A Quality Management (QM) Plan I. Introduction Baltimore-Towson EMA Part A Quality Management (QM) Plan 2009-2011 I. Introduction The Baltimore City Health Department (BCHD) is designated the Ryan White Part A Grantee and manages the Clinical Quality

More information

Proposed amendments to the Marihuana for Medical Purposes Regulations

Proposed amendments to the Marihuana for Medical Purposes Regulations Proposed amendments to the Marihuana for Medical Purposes Regulations Submission in response to the Canada Gazette publication on the proposed amendments to the Marihuana for Medical Purposes Regulations

More information

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland

Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective DIA Europe 2018-17-19 April Basel, Switzerland Presented by Xavier Kurz Head of Service Surveillance and Epidemiology

More information

SKAC240 Manage health, safety, security and welfare in sport and active leisure

SKAC240 Manage health, safety, security and welfare in sport and active leisure Manage health, safety, security and welfare in sport and active leisure Overview Health, safety, security and welfare are of vital importance in sport and active leisure. Incidents may occur that will

More information

HUMAN RESOURCES POLICY

HUMAN RESOURCES POLICY North of England Clinical Commissioning Groups HUMAN RESOURCES POLICY PROFESSIONAL REGISTRATION Policy Number: HR24 Version Number: 3.0 Issued Date: March 2017 Review Date: March 2020 Sponsoring Director:

More information

SOP Title: Reporting Adverse Events and New Safety Information

SOP Title: Reporting Adverse Events and New Safety Information Page 1 of 14 General Control of medication use requires collecting field data about adverse events (AEs) resulting from medication therapy. Regulation 7(B)(2) of Pharmacists Regulations (Medical Products)

More information

3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION

3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION 1 PURPOSE The purpose of this procedure is to describe the method by which Adverse Events (AE)/relevant Safety Information and Product Quality Complaints (PQC) will be received, triaged, and documented

More information

European Patients Academy (EUPATI) Update

European Patients Academy (EUPATI) Update European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to

More information

SFHPHARM11 - SQA Unit Code FA2X 04 Prepare extemporaneous medicines for individual use

SFHPHARM11 - SQA Unit Code FA2X 04 Prepare extemporaneous medicines for individual use Prepare extemporaneous medicines for individual use Overview This standard covers your role in preparing extemporaneous medicines for individual use. This involves accurately calculating the quantities

More information

HEALOGICS, INC. ~ VENDOR CODE OF CONDUCT

HEALOGICS, INC. ~ VENDOR CODE OF CONDUCT HEALOGICS, INC. ~ VENDOR CODE OF CONDUCT Updated October 2015 Contents Section 1: Introduction... 3 Section 2: Vendor Visits to Centers... 4 Section 3: Educational Activities... 6 Section 4: Free Incentives

More information

Role Profile Medical Officer- Medical Devices

Role Profile Medical Officer- Medical Devices Role Profile Medical Officer- Medical Devices ROLE SUMMARY The Medical Officer role will be within the Medical Devices department. Reporting to the Deputy Director Medical Devices, the role of the Medical

More information

Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Specialised Therapeutics Australia Pty. Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances

More information

Table 1. Big Data Sources of Interest for Pharmacovigilance (PV)

Table 1. Big Data Sources of Interest for Pharmacovigilance (PV) Health Sciences Authority, Singapore 1 National Electronic Health Electronic Health Record Interest Preliminary stage, exploring access to records Record 2 Electronic medical records Laboratory data, discharge

More information

Finance. Date to Committee: March 26, 2013 Date to Council: April 8, 2013

Finance. Date to Committee: March 26, 2013 Date to Council: April 8, 2013 Page 1 of Report F-12-13 Finance TO: Budget and Corporate Services Committee SUBJECT: Green Procurement Initiatives Update Report Number: F-12-13 File Number(s): Report Date: January 5, 2013 Ward(s) Affected:

More information

Report of an inspection of a Designated Centre for Disabilities (Children)

Report of an inspection of a Designated Centre for Disabilities (Children) Report of an inspection of a Designated Centre for Disabilities (Children) Name of designated centre: Name of provider: Cliff House Address of centre: Dublin 3 Stepping Stones Residential Care Limited

More information

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018

Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Legislations and Policies in Jordan/ Related to Health and Pharmaceuticals April 19, 2018 Dr. Rania Bader, HRH2030 Health Workforce Competency Lead HRH2030 The Human Resources for Health (HRH2030) is a

More information

CPD Cycle from 1 January 2013/2014/2015 to 31 December 2013/2014/2015. Notes. Solicitor s Name:

CPD Cycle from 1 January 2013/2014/2015 to 31 December 2013/2014/2015. Notes. Solicitor s Name: THE CONTINUING PROFESSIONAL DEVELOPMENT SCHEME RECORD CARD CPD Cycle from 1 January 2013/2014/2015 to 31 December 2013/2014/2015 (delete as appropriate) Solicitor s Name: When admitted to the Roll of Solicitors

More information

Information Brochure Professional Certificate in Pharmacovigilance

Information Brochure Professional Certificate in Pharmacovigilance Information Brochure Professional Certificate in Pharmacovigilance Catalyst Clinical Services Pvt. Ltd. Unit No. 11, CSC-12, Block D1, Sector-16, Rohini, Delhi - 110089 (India) M: +91 9818356273 Email:

More information

Managing medicines in care homes

Managing medicines in care homes Managing medicines in care homes http://www.nice.org.uk/guidance/sc/sc1.jsp Published: 14 March 2014 Contents What is this guideline about and who is it for?... 5 Purpose of this guideline... 5 Audience

More information

Details: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure

Details: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure Details: Author: Razwan Mahroof - QA Clinical Trials Monitor SOP Pages: 10 Version No. of replaced SOP: 1.0 Effective date of replaced SOP: 04 December 2015 Approval: Version No: of the SOP being approved.

More information